Type

Issue

Tag

2023 Hospital Social Responsibility: Event Recap

Over 3,600 hospitals were evaluated across the nation. Fifty-four earned A’s across the three main categories of equity, value, and outcomes, earning them Honor Roll status. To have a socially responsible healthcare system, we need more hospitals performing better on metrics like pay equity, racial inclusivity, and community investment. So how do we accomplish this goal?  More

Why more mammograms aren’t the solution to breast cancer

A recent analysis by the Lown Institute, a nonprofit health care think tank, highlighted some key USPSTF figures that show the limits of mammograms in a helpful way. The analysis imagines a world without screening mammograms, in which women seek evaluation for breast cancer only when they notice a breast lump or other concerning symptoms. According to the USPSTF’s models, about 28 out of every 1,000 women in this world would die from breast cancer at some point in their lives.

More

Balancing prevention and overdiagnosis in skin cancer screening

A recent editorial published in JAMA Dermatology discussed the balance between prevention and overdiagnosis of skin cancer. This comes in response to the U.S. Preventive Services Task Force concluding for the fourth time in a row that visual skin cancer screening has insufficient evidence to support its population-wide benefit. How do we know when we’ve crossed from prevention to overuse, and is there anything we can do to keep the balance? More

Too many people take too many pills

“Polypharmacy”, as doctors call it, imposes a big drag on health. A recent study at a hospital in Liverpool found that nearly one in five hospital admissions was caused by adverse reactions to drugs. The Lown Institute, an American think-tank, reckons that, between 2020 and 2030, medication overload in America could cause more than 150,000 premature deaths and 4.5m hospital admissions. More

Penn Medicine is going all in on proton therapy, a costly treatment that is unproven for most common cancers

The explosive growth worries Vikas Saini, a cardiologist and president of the Lown Institute, a think tank that examines quality, cost, and equity across health care. He said doctors are prescribing proton therapy in a gray area — they think it may be better for a patient than the cheaper alternative, but there’s no hard proof.
“Everybody knows the game: You get an approval, and you go out on the market, then you expand the indications,” Saini said. “It’s called indication creep, or scope creep.”
More